Kyle C. Molina

Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study

Neil Krishan Aggarwal, Kyle C. Molina, Laurel Beaty et al. · The Lancet Infectious Diseases · 2023 · 145 citations · Full text

Medicine, Infectious Diseases, Internal Medicine +14

Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i>

Sara Alosaimy, Abdalhamid M Lagnf, Taylor Morrisette et al. · Open Forum Infectious Diseases · 2021 · 57 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Early Experience With Eravacycline for Complicated Infections

Sara Alosaimy, Kyle C. Molina, Kimberly C. Claeys et al. · Open Forum Infectious Diseases · 2020 · 54 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +8

Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii

Sara Alosaimy, Taylor Morrisette, Abdalhamid M Lagnf et al. · Microbiology Spectrum · 2022 · 54 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care

Tanner M Johnson, Kyle C. Molina, Matthew A. Miller et al. · International Journal of Antimicrobial Agents · 2021 · 48 citations

Pharmacy, Infectious Diseases, Microbiology +16